Prazosin, a minuscule molecule drug, exhibits antagonistic properties towards α1A-AR, α1B-AR, and α1D-AR receptors. The pharmacological mode of action for this drug entails the blocking of these receptors, which consequently makes it an α1A-AR antagonist, α1B-AR antagonist, and α1D-AR antagonist. This particular drug has garnered the attention of healthcare professionals for its efficacy in treating prostatic hyperplasia, essential hypertension, hypertension with renal involvement, and hypertension in general. Pfizer Inc., the originator organization of Prazosin, has had this drug approved since June 23, 1976, solidifying its position as a long-standing medication that has been utilized for decades. Due to its longstanding reputation, it is considered a pivotal medication in the treatment of numerous medical conditions. Click on the image below to begin the exploration journey of Prazosin through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!